{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T22:19:46Z","timestamp":1757456386020,"version":"3.41.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00280-025-04792-7","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T04:15:20Z","timestamp":1751429720000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pazopanib and antacids: insights from the WHO pharmacovigilance database"],"prefix":"10.1007","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0367-8557","authenticated-orcid":false,"given":"Kazuki","family":"Nishida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2365-1513","authenticated-orcid":false,"given":"Yao","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4700-6541","authenticated-orcid":false,"given":"Osamu","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8193-5144","authenticated-orcid":false,"given":"Ang\u00e9lique Da","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6849-2297","authenticated-orcid":false,"given":"Yuichi","family":"Ando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7483-2489","authenticated-orcid":false,"given":"Basile","family":"Chr\u00e9tien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"4792_CR1","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1093\/jjco\/hyy053","volume":"48","author":"S Miyamoto","year":"2018","unstructured":"Miyamoto S, Kakutani S, Sato Y et al (2018) Drug review: pazopanib. Jpn J Clin Oncol 48:503\u2013513. https:\/\/doi.org\/10.1093\/jjco\/hyy053","journal-title":"Jpn J Clin Oncol"},{"key":"4792_CR2","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s40360-018-0264-8","volume":"19","author":"MJ M\u00e9ndez-Vidal","year":"2018","unstructured":"M\u00e9ndez-Vidal MJ, Molina \u00c1, Anido U et al (2018) Pazopanib: evidence review and clinical practice in the management of advanced renal cell carcinoma. BMC Pharmacol Toxicol 19:77. https:\/\/doi.org\/10.1186\/s40360-018-0264-8","journal-title":"BMC Pharmacol Toxicol"},{"key":"4792_CR3","unstructured":"Votrient 400\u00a0mg film coated tablets-Summary of Product Characteristics (SmPC)-(emc). https:\/\/www.medicines.org.uk\/emc\/product\/572\/smpc. Accessed 4 Mar 2025"},{"key":"4792_CR4","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1007\/s00280-013-2164-3","volume":"71","author":"AR Tan","year":"2013","unstructured":"Tan AR, Gibbon DG, Stein MN et al (2013) Effects of ketoconazole and Esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors. Cancer Chemother Pharmacol 71:1635\u20131643. https:\/\/doi.org\/10.1007\/s00280-013-2164-3","journal-title":"Cancer Chemother Pharmacol"},{"key":"4792_CR5","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/cts.12648","volume":"12","author":"SG Pisano","year":"2019","unstructured":"Pisano SG, Hoffman SE, Legasto CS et al (2019) Effect of Acid-Suppressive strategies on pazopanib efficacy in patients with Soft\u2010Tissue sarcoma. Clin Transl Sci 12:529\u2013533. https:\/\/doi.org\/10.1111\/cts.12648","journal-title":"Clin Transl Sci"},{"key":"4792_CR6","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1002\/ijc.33469","volume":"148","author":"SD Krens","year":"2021","unstructured":"Krens SD, Lubberman FJE, van Egmond M et al (2021) The impact of a 1-hour time interval between pazopanib and subsequent intake of gastric acid suppressants on pazopanib exposure. Int J Cancer 148:2799\u20132806. https:\/\/doi.org\/10.1002\/ijc.33469","journal-title":"Int J Cancer"},{"key":"4792_CR7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s13691-023-00638-2","volume":"13","author":"Y Liang","year":"2023","unstructured":"Liang Y, Maeda O, Shimokata T et al (2023) Potential drug interactions between pazopanib and proton pump inhibitors\/potassium-competitive acid blockers in patients with soft tissue sarcoma. Int Cancer Conf J 13:63\u201367. https:\/\/doi.org\/10.1007\/s13691-023-00638-2","journal-title":"Int Cancer Conf J"},{"key":"4792_CR8","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1097\/CAD.0000000000001356","volume":"34","author":"S Buti","year":"2023","unstructured":"Buti S, Tommasi C, Scartabellati G et al (2023) The impact of proton-pump inhibitors administered with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma. Anticancer Drugs 34:178\u2013186. https:\/\/doi.org\/10.1097\/CAD.0000000000001356","journal-title":"Anticancer Drugs"},{"key":"4792_CR9","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1634\/theoncologist.2017-0578","volume":"23","author":"RK McAlister","year":"2018","unstructured":"McAlister RK, Aston J, Pollack M et al (2018) Effect of concomitant pH-Elevating medications with pazopanib on Progression\u2010Free survival and overall survival in patients with metastatic renal cell carcinoma. Oncologist 23:686\u2013692. https:\/\/doi.org\/10.1634\/theoncologist.2017-0578","journal-title":"Oncologist"},{"key":"4792_CR10","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1007\/s00228-020-02902-3","volume":"76","author":"G Van De Sijpe","year":"2020","unstructured":"Van De Sijpe G, Beuselinck B, Van Nieuwenhuyse T et al (2020) Impact of concomitant acid suppressive therapy on pazopanib efficacy and dose reductions in patients with metastatic renal cell carcinoma. Eur J Clin Pharmacol 76:1273\u20131280. https:\/\/doi.org\/10.1007\/s00228-020-02902-3","journal-title":"Eur J Clin Pharmacol"},{"key":"4792_CR11","unstructured":"(2024) Safety Reporting and Pharmacovigilance| NIAID: National Institute of Allergy and Infectious Diseases. https:\/\/www.niaid.nih.gov\/research\/dmid-safety-reporting-pharmacovigilance. Accessed 16 Jun 2025"},{"key":"4792_CR12","unstructured":"Centre UM About VigiBase. https:\/\/who-umc.org\/vigibase\/. Accessed 20 Apr 2023"},{"key":"4792_CR13","unstructured":"Record growth pushes VigiBase past 28 million reports. In: Uppsala Reports. https:\/\/uppsalareports.org\/articles\/record-growth-pushes-vigibase-past-28-million-reports\/. Accessed 16 Jun 2025. (20240416)"},{"key":"4792_CR14","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s00280-023-04615-7","volume":"93","author":"K Westerdijk","year":"2024","unstructured":"Westerdijk K, Krens SD, Steeghs N et al (2024) Real-world data on the management of pazopanib-induced liver toxicity in routine care of renal cell cancer and soft tissue sarcoma patients. Cancer Chemother Pharmacol 93:353\u2013364. https:\/\/doi.org\/10.1007\/s00280-023-04615-7","journal-title":"Cancer Chemother Pharmacol"},{"key":"4792_CR15","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s11912-018-0708-8","volume":"20","author":"M Agarwal","year":"2018","unstructured":"Agarwal M, Thareja N, Benjamin M et al (2018) Tyrosine kinase Inhibitor-Induced hypertension. Curr Oncol Rep 20:65. https:\/\/doi.org\/10.1007\/s11912-018-0708-8","journal-title":"Curr Oncol Rep"},{"key":"4792_CR16","doi-asserted-by":"publisher","first-page":"e27531","DOI":"10.1016\/j.heliyon.2024.e27531","volume":"10","author":"J Liu","year":"2024","unstructured":"Liu J, Yan S, Du J et al (2024) Mechanism and treatment of diarrhea associated with tyrosine kinase inhibitors. Heliyon 10:e27531. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e27531","journal-title":"Heliyon"},{"key":"4792_CR17","doi-asserted-by":"publisher","first-page":"102794","DOI":"10.1016\/j.ctrv.2024.102794","volume":"129","author":"J-L Raoul","year":"2024","unstructured":"Raoul J-L, Hansten PD (2024) Proton pump inhibitors and cancer treatments: emerging evidence against coadministration. Cancer Treat Rev 129:102794. https:\/\/doi.org\/10.1016\/j.ctrv.2024.102794","journal-title":"Cancer Treat Rev"},{"key":"4792_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.14309\/ajg.0000000000001538","volume":"117","author":"PO Katz","year":"2022","unstructured":"Katz PO, Dunbar KB, Schnoll-Sussman FH et al (2022) ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease. Official J Am Coll Gastroenterol| ACG 117:27. https:\/\/doi.org\/10.14309\/ajg.0000000000001538","journal-title":"Official J Am Coll Gastroenterol| ACG"},{"key":"4792_CR19","doi-asserted-by":"publisher","first-page":"100995","DOI":"10.1016\/j.dmpk.2024.100995","volume":"55","author":"HJ Muhammad","year":"2024","unstructured":"Muhammad HJ, Shimada T, Fujita A, Sai Y (2024) Sodium citrate buffer improves pazopanib solubility and absorption in gastric acid-suppressed rat model. Drug Metab Pharmacokinet 55:100995. https:\/\/doi.org\/10.1016\/j.dmpk.2024.100995","journal-title":"Drug Metab Pharmacokinet"},{"key":"4792_CR20","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1200\/JCO.2015.65.2560","volume":"34","author":"RWF van Leeuwen","year":"2016","unstructured":"van Leeuwen RWF, Peric R, Hussaarts KGAM et al (2016) Influence of the acidic beverage Cola on the absorption of erlotinib in patients with Non\u2013Small-Cell lung Cancer. JCO 34:1309\u20131314. https:\/\/doi.org\/10.1200\/JCO.2015.65.2560","journal-title":"JCO"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04792-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-025-04792-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04792-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T04:15:25Z","timestamp":1751429725000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-025-04792-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4792"],"URL":"https:\/\/doi.org\/10.1007\/s00280-025-04792-7","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"4 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted in accordance with applicable ethical guidelines and regulatory standards for pharmacovigilance research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"66"}}